These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 29250788

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of clinical sensitivity and specificity of hepatitis B virus (HBV), hepatitis C virus, and human immunodeficiency Virus-1 by cobas MPX: Detection of occult HBV infection in an HBV-endemic area.
    Ha J, Park Y, Kim HS.
    J Clin Virol; 2017 Nov; 96():60-63. PubMed ID: 28982042
    [Abstract] [Full Text] [Related]

  • 4. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L, Chen PJ, Chen MH, Chak KF, Lin KS, Tsai SJ.
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [Abstract] [Full Text] [Related]

  • 5. Comparative analysis of triplex nucleic acid test assays in United States blood donors.
    Stramer SL, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Dodd RY, Kleinman SH.
    Transfusion; 2013 Oct; 53(10 Pt 2):2525-37. PubMed ID: 23550838
    [Abstract] [Full Text] [Related]

  • 6. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA.
    Margaritis AR, Brown SM, Seed CR, Kiely P, D'Agostino B, Keller AJ.
    Transfusion; 2007 Oct; 47(10):1783-93. PubMed ID: 17880602
    [Abstract] [Full Text] [Related]

  • 7. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
    Nübling CM, Chudy M, Volkers P, Löwer J.
    Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
    [Abstract] [Full Text] [Related]

  • 8. HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas TaqScreen MPX test in seroconverting donors.
    Wiedmann M, Kluwick S, Walter M, Fauchald G, Howe J, Bronold M, Zauke M.
    J Clin Virol; 2007 Aug; 39(4):282-7. PubMed ID: 17611148
    [Abstract] [Full Text] [Related]

  • 9. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM, Unkelbach U, Chudy M, Seitz R.
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [Abstract] [Full Text] [Related]

  • 10. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C, Romanò L, Fomiatti L, Baruffi L, Zanetti AR, SIMTI Research Group.
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [Abstract] [Full Text] [Related]

  • 11. Routine screening of blood donations at Qingdao central blood bank, China, for hepatitis B virus (HBV) DNA with a real-time, multiplex nucleic acid test for HBV, hepatitis C virus, and human immunodeficiency virus Types 1 and 2.
    Yang Z, Xu L, Liu L, Feng Q, Zhang L, Ma W, Saldanha J, Wang M, Zhao L.
    Transfusion; 2013 Oct; 53(10 Pt 2):2538-44. PubMed ID: 23480568
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan.
    Mine H, Emura H, Miyamoto M, Tomono T, Minegishi K, Murokawa H, Yamanaka R, Yoshikawa A, Nishioka K, Japanese Red Cross NAT Research Group.
    J Virol Methods; 2003 Sep; 112(1-2):145-51. PubMed ID: 12951223
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Detection of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in postmortem blood specimens using infectious disease assays licensed for cadaveric donor screening.
    Greenwald MA, Kerby S, Francis K, Noller AC, Gormley WT, Biswas R, Forshee RA.
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178465
    [Abstract] [Full Text] [Related]

  • 16. Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes.
    Schmidt M, Pichl L, Jork C, Hourfar MK, Schottstedt V, Wagner FF, Seifried E, Müller TH, Bux J, Saldanha J.
    Vox Sang; 2010 Jan; 98(1):37-46. PubMed ID: 19682348
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection.
    Koppelman MH, Sjerps MC, Reesink HW, Cuypers HT.
    Vox Sang; 2005 Nov; 89(4):193-200. PubMed ID: 16262751
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The characteristics of hepatitis B surface antigen (HBsAg)-negative hepatitis B virus (HBV) infection in Chinese blood donors: a follow-up study of donors tested negative for HBsAg and reactive for simultaneous nucleic acid testing of HBV, hepatitis C virus, and human immunodeficiency virus.
    Guo Z, Fu P, Yin Y, Wang F, Yin Y, Wang J, Liu Y.
    Transfusion; 2017 Mar; 57(3pt2):832-840. PubMed ID: 28164313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.